These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 15452367)

  • 1. Treatment with buserelin, an agonist of gonadotropin-releasing hormone, suppresses ovarian hyperstimulation syndrome induced in rabbits.
    Oshima K; Suzuki K; Makita S; Yoshida Y
    Pharmacology; 2004 Nov; 72(3):184-9. PubMed ID: 15452367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of GnRH analog for induction of the ovulatory surge of gonadotropins in patients at risk of the ovarian hyperstimulation syndrome.
    Kulikowski M; Wołczyński S; Kuczyński W; Grochowski D; Szamatowicz M
    Gynecol Endocrinol; 1995 Jun; 9(2):97-102. PubMed ID: 7502696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
    Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
    Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of triggering oocyte maturation with a GnRH agonist in polycystic ovary syndrome: two case reports.
    Honnma H; Hashiba Y; Asada Y; Endo T
    Eur J Obstet Gynecol Reprod Biol; 2011 Aug; 157(2):239-40. PubMed ID: 21477915
    [No Abstract]   [Full Text] [Related]  

  • 6. Failure to improve ovarian response by combined gonadotropin-releasing hormone agonist and gonadotropin therapy.
    Bider D; Kokia E; Lipitz S; Blankstein J; Mashiach S; Serr DM; Ben-Rafael Z
    Gynecol Obstet Invest; 1990; 29(3):192-6. PubMed ID: 2113505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian hyperstimulation: effects of GnRH analogues. Does triggering ovulation with gonadotrophin-releasing hormone analogue prevent severe ovarian hyperstimulation syndrome?
    Casper RF
    Hum Reprod; 1996 Jun; 11(6):1144-6. PubMed ID: 8671408
    [No Abstract]   [Full Text] [Related]  

  • 8. Ovarian response and pregnancy rates in in vitro fertilization, gamete intrafallopian transfer, and in vivo fertilization therapies after combined gonadotropin-releasing hormone agonist/human menopausal gonadotropin stimulation.
    Lindner C; Braendle W; Lichtenberg V; Köhler S; Bettendorf G
    Gynecol Obstet Invest; 1990; 29(2):140-4. PubMed ID: 2139861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of intravenous immunoglobulin in the prevention of severe ovarian hyperstimulation syndrome.
    Orvieto R; Achiron A; Margalit R; Ben-Rafael Z
    J Assist Reprod Genet; 1998 Jan; 15(1):46-9. PubMed ID: 9493066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5.
    Kitajima Y; Endo T; Nagasawa K; Manase K; Honnma H; Baba T; Hayashi T; Chiba H; Sawada N; Saito T
    Endocrinology; 2006 Feb; 147(2):694-9. PubMed ID: 16269461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of GnRH analogue (buserelin) or hCG (Chorulon) on Day 12 of pregnancy on ovarian function, plasma hormone concentrations, conceptus growth and placentation in ewes and ewe lambs.
    Khan TH; Beck NF; Khalid M
    Anim Reprod Sci; 2007 Dec; 102(3-4):247-57. PubMed ID: 17174489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A controlled study of gonadotropin-releasing hormone agonist (buserelin acetate) for folliculogenesis in routine in vitro fertilization patients.
    Polson DW; MacLachlan V; Krapez JA; Wood C; Healy DL
    Fertil Steril; 1991 Sep; 56(3):509-14. PubMed ID: 1909978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short coasting of 1 or 2 days by withholding both gonadotropins and gonadotropin-releasing hormone agonist prevents ovarian hyperstimulation syndrome without compromising the outcome.
    Moon HS; Joo BS; Moon SE; Lee SK; Kim KS; Koo JS
    Fertil Steril; 2008 Dec; 90(6):2172-8. PubMed ID: 18439601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pentoxifylline in the prevention of ovarian hyperstimulation syndrome in a rabbit model.
    Serin IS; Ozçelik B; Bekyurek T; Ozturk F; Koc N; Sahin Y
    Gynecol Endocrinol; 2002 Oct; 16(5):355-9. PubMed ID: 12587528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of enalapril in the prevention of ovarian hyperstimulation syndrome: a rabbit model.
    Gul TG; Posaci C; Caliskan S
    Hum Reprod; 2001 Nov; 16(11):2253-7. PubMed ID: 11679499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of gonadotropin-releasing hormone agonists, nafarelin, buserelin, and leuprolide, on experimentally induced endometriosis in the rat.
    Mizutani T; Sakata M; Terakawa N
    Int J Fertil Menopausal Stud; 1995; 40(2):106-11. PubMed ID: 7599657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of angiotensin converting enzyme inhibitor cilazapril and angiotensin II antagonist saralasin in ovarian hyperstimulation syndrome in the rabbit.
    Sahin Y; Kontaş O; Müderris II; Cankurtaran M
    Gynecol Endocrinol; 1997 Aug; 11(4):231-6. PubMed ID: 9272418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose human chorionic gonadotropin versus estradiol/progesterone luteal phase support in gonadotropin-releasing hormone agonist-triggered assisted reproductive technique cycles: understanding a new approach.
    Garcia-Velasco JA; Motta L; López A; Mayoral M; Cerrillo M; Pacheco A
    Fertil Steril; 2010 Dec; 94(7):2820-3. PubMed ID: 20673892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study.
    Pirard C; Donnez J; Loumaye E
    Hum Reprod; 2006 Jul; 21(7):1894-900. PubMed ID: 16556673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.